Hepatitis B virus: Inactive carriers

Virology Journal

Volumn 2, Issue , 2005, Pages

  Chwla, Yogesh ^a  

^a POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIBODY; VIRUS DNA;

ANTIBODY DETECTION; ARTICLE; CANCER RISK; CHRONIC HEPATITIS; CLINICAL FEATURE; DISEASE ACTIVITY; DISEASE COURSE; DNA DETERMINATION; FOLLOW UP; HEPATITIS B; HEPATITIS B VIRUS; HISTOPATHOLOGY; HISTORY; HUMAN; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER DISEASE; LIVER FIBROSIS; LIVER NECROSIS; NOMENCLATURE; PATIENT CARE; POLYMERASE CHAIN REACTION; PREVALENCE; PROGNOSIS; REMISSION; VIRUS CARRIER; VIRUS DETECTION; VIRUS DIAGNOSIS; VIRUS REACTIVATION; VIRUS REPLICATION;

HEPATITIS B VIRUS;

EID: 26844559785     PISSN: 1743422X     EISSN: 1743422X     Source Type: Journal    
DOI: 10.1186/1743-422X-2-82     Document Type: Article

References (50)

1. Maddrey WC: Hepatitis B: an important public health issue. J Med Virol 2000, 61:362-366.
2. Lee WM: Hepatitis B virus infection. N Engl J Med 1997, 337:1733-1745.
3. Lok AS, Heathcote EJ, Hoofnagle JH: Management of hepatitis B: 2000 - summary of a workshop. Gastroenterology 2001, 120:1828-1853.
4. Lok ASF, McMahon BJ: Chronic hepatitis B. Hepatology 2001, 34:1225-1241.
5. Seegar C, Mason WS: Hepattits B virus: the major etiology of hepatocellular carcinoma. Cancer 1988, 61:9142-56.
6. Margolis HS, Alter MJ, Hadier SC: Hepatitis B: evolving epidemiology and implications for control. Semin Liver Dis 1991, 11:84-92.
7. Beasley RP, Hwang LY, Lee GC, et al.: Prevention of perinatally transmitted hepatitis B virus infections with hepatitis B immune globulin and hepatitis B vaccine. Lancet 1983, 2:1099-1102.
8. Lee WM: Hepatitis B virus infection. N Engl J Med 1997, 337:1733-1745.
9. McQuillan GM, Townsend TR, Fields HA, Carrol M, Leahy M, Polk BF: Seroepidemiology of hepatitis B virus infection in the United States. Am J Med 1989, 87(suppl 3A):5S-10S.
10. CDC Immunization Practices Advisory Committee (ACIP): Hepatitis B Virus: A comprehensive strategy for limiting transmission in the United States through universal childhood vaccination. MMWR Morb Mortal Wkly Rep 1991, 40(RR-13):1-25.
11. Milich DR, Chen MK, Hughes JL, Jones JE: The secreted hepatitis B precore antigen can modulate the immune response to the nucleocapsid: a mechanism for persistence. J Immunol 1998, 160:2013-2021.
12. Chemin I, Zoulim F, Merle P, et al.: High incidence of hepatitis B infections among chronic hepatitis cases of unknwon aetiology. J Hepatol 2001, 34:471-473.
13. Kawatani T, Suou T, Tajima F, et al.: Incidence of hepatitis virus infection and severe liver dysfunction in patients receiving chemotherapy for hematologic malignancies. Eur J Haematol 2001, 67:45-50.
14. Burk RD, Hwang LY, Ho GYF, Shafritz DA, Beasley RP: Outcome of perinatal hepatitis B virus exposure is dependent on maternal virus load. J Infect Dis 1994, 170:1418-1423.
15. Cacciola I, Cerenzia G, Pollicino T, et al.: Genomic heterogeneity of hepatitis B virus (HBV) and outcome of perinatal HBV infection. J Hepatol 2002, 36:426-432.
16. Hoofnagle JH, Dusheiko GM, Seef LB, et al.: Seroconversion from hepatitis B e antigen to antibody in chronic type B hepatitis. Ann Intern Med 1981, 94:744-748.
17. Fattovich G, Rugge M, Brollo L, et al.: Clinical, virologic and histologic outcome following seroconversion from HBeAg to anti-HBe in chronic hepatitis type B. Hepatology 1986, 6:167-172.
18. Moreno-Otero R, Garcia-Monzòn C, Garcia-Sànchez A, et al.: Development of cirrhosis after chronic type B hepatitis: a clinicopathologic and follow-up study of 46 HBeAg-positiveasymptomatic patients. Am J Gastroenterol 1991, 86:560-564.
19. Zarski JP, Marcellin P, Cohard M, et al.: Comparison of anti-HBe-positive and HBe-antigen-positive chronic hepatitis B in France. J Hepatol 1994, 20:636-640.
20. Di Marco V, Lo Iacono O, Cammà C, et al.: The long-term course of chronic hepatitis B. Hepatology 1999, 30:257-264.
21. Chang MH, Hsu HY, Hsu HC, et al.: The significance of spontaneous hepatitis B e antigen seroconversion in childhood: with special emphasis on the clearance of hepatitis B e antigen before 3 years of age. Hepatology 1995, 22:1387-1392.
22. Bortolotti F, Jara P, Crivellaro C, et al.: Outcome of chronic hepatitis B in Caucasian children during a 20-year observation period. J Hepatol 1998, 29:184-190.
23. CDC. Hepatitis B virus: a comprehensive strategy for limiting transmission in the United States through universal child vaccination. Recommendation of the Immunization Practice Advisory Committee (ACIP). MMWR 1991;40:RR-13:1-25
24. Realdi G, Alberti A, Rugge M, et al.: Seroconversion from hepatitis B e antigen to anti-HBe in chronic hepatitis B virus infection. Gastroenterology 1980, 79:195-199.
25. Hoofnagle JH, Dusheiko GM, Seef LB, et al.: Seroconversion from hepatitis B e antigen to antibody in chronic type B hepatitis. Ann Intern Med 1981, 94:744-748.
26. Fattovich G, Rugge M, Brollo L, et al.: Clinical, virologic and histologic outcome following seroconversion from HBeAg to anti-HBe in chronic hepatitis type B. Hepatology 1986, 6:167-172.
27. Fong TL, Di Bisceglie AM, Gerber MA, Waggoner JG, Hoofnagle JH: Persistence of hepatitis B virus DNA in the liver after loss of HBsAg in chronic hepatitis B. Hepatology 1993, 18:1313-1318.
28. Yuen MF, Hui CK, Cheng CC, et al.: Long-term follow-up of interferon alfa treatment in Chinese patients with chronic hepatitis B infection: the effect on hepatitis B e antigen seroconversion and the development of cirrhosis-related complications. Hepatology 2001, 34:139-145.
29. McMahon BJ, Holck P, Bulkow L, Snowball M: Serologic and clinical outcomes of 1536 Alaska natives chronically infected with hepatitis B virus. Ann Intern Med 2001, 135:759-768.
30. Bortolotti F, Cadrobbi P, Crivellaro C, et al.: Long-term outcome of chronic type B hepatitis in patients who acquire hepatitis B virus infection in childhood. Gastroenterology 1990, 99:805-810.
31. Wong DKH, Cheung AM, O'Rourke K, et al.: Effect of alpha-interferon treatment in patients with hepatitis B e antigen positive chronic hepatitis B. A meta-analysis. Ann Intern Med 1993, 119:312-323.
32. Vajro P, Migliaro F, Fontanella A, Orso G: Interferon: a meta-analysis of published studies in pediatric chronic hepatitis B. Acta Gastroenterol Belg 1998, 61:219-223.
33. Chang MH, Sung JL, Lee CY, et al.: Factors affecting clearance of hepatitis B e antigen in hepatitis B surface antigen carrier children. J Pediatr 1989, 115:385-390.
34. Lok ASF, Lai CL, Wu PC, Leung EKY, Lam TS: Spontaneous hepatitis B e antigen to antibody seroconversion and reversion in Chinese patients with chronic hepatitis B virus infection. Gastroenterology 1987, 92:1839-1843.
35. Perillo RP: Acute flares in chronic hepatitis B: the natural and unnatural history of an immunologically mediated liver disease. Gastroenterology 2001, 120:1009-1022.
36. Hadziyannis SJ, Vassilopoulos D: Hepatitis B e antigennegative chronic hepatitis B. Hepatology 2001, 34:617-624.
37. Chan HLY, Leung NWY, Hussain M, Wong ML, Lok ASF: Hepatitis B e antigen-negative chronic hepatitis B in Hong Kong. Hepatology 2000, 31:763-768.
38. Fattovich G, Farci P, Rugge M, et al.: Randomized controlled trial of lymphoblastoid interferon alfa in patients with chronic hepatitis B who lacked hepatitis B e antigen. Hepatology 1992, 15:584-589.
39. Lampertico P, Del Ninno E, Manzin A, et al.: A randomized, controlled trial of a 24-month course of interferon alfa 2b in patients with chronic hepatitis B who had hepatitis B virus DNA without hepatitis B e antigen in serum. Hepatology 1997, 26:1621-1625.
40. Tassopoulos NC, Volpes R, Pastore G, et al.: Efficacy of lamivudine in patients with hepatitis B e antigen negative hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Lamivudine Precore Mutant Group. Hepatology 1999, 29:889-896.
41. Hsu YS, Chien RN, Yeh CT, et al.: Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B. Hepatology 2002, 35:1522-1527.
42. De Franchis R, Meucci G, Vecchi M, et al.: The natural history of asymptomatic hepatitis B surface antigen carriers. Ann Intern Med 1993, 118:191-194.
43. Bellentani S, Dal Molin G, Miglioli L, et al.: Natural history of HBV infection: a 9 years follow-up of the Dionysos cohort. J Hepatol 2002, 36(Suppl 1):228.
44. Fattovich G, Giustina G, Realdi G, Corrocher R, Schalm SW: Longterm outcome of hepatitis B e antigen positive patients with compensated cirrhosis treated with interferon alfa. Hepatology 1997, 26:1338-1342.
45. Tassopoulos NC, Papaevangelou GJ, Sjogren MH, et al.: Natural history of acute hepatitis B surface antigen-positive hepatitis in Greek adults. Gastroenterology 1987, 92:1844-1850.
46. Fattovich G, Giustina G, Sanchez-Tapias J, et al.: Delayed clearance of serum HBsAg in compensated cirrhosis B: relation to interferon alpha therapy and disease prognosis. Am J Gastroenterol 1998, 93:896-900.
47. Huo TI, Wu JC, Lee PC, et al.: Sero-clearance of hepatitis B surface antigen in chronic carriers not necessarily implies a good prognosis. Hepatology 1998, 28:231-236.
48. Sarin Sk: Summary and recommendations of single theme conferences on hepatitis B and C: Indian association for study of the liver (INASL). J gastro hepatol 2002, 17:S197-S203.
49. Sarin SK, Sathpathy SK, Chauhan R: Hepatitis B e-antigen negative chronic hepatitis B. J gastro hepatol 2002, 17:S311-S321.
50. EASL international consensus conference on hepatitis B. Journal of Hepatology 2003, 39:S3-S25.